About the Study
We are testing if fecal microbiota transplant is effective in treating C. difficile (also known as C. diff) infection in solid organ transplant recipients.
This study is for solid organ transplant recipients who have a recurrence of C. diff infection after their transplant. Organ transplant recipients may take medications that can disrupt normal gut bacteria, such as immunosuppressant drugs and antibiotics. As a result, organ transplant recipients have high rates of C. diff infection.
The conventional treatment for C. diff is a medication called vancomycin. This study is testing if fecal microbiota transplantation can be used to safely treat C. diff in organ transplant recipients.
Learn about the protocolWhat is a fecal microbiota transplant (FMT)?
A fecal microbiota transplant (FMT) is a procedure in which fecal matter, or stool, is collected from a healthy donor, filtered and frozen with a preservative or another solution, freeze-fried and placed into a capsule to be given to another person. The goal of FMT is to reintroduce good bacteria into the colon that may have been killed or suppressed and caused bad bacteria to thrive, specifically C. difficile.
What is the RECOVER clinical trial?
RECOVER is a double-blind clinical trial for solid organ transplant recipients that have had a recurrence of C. diff. Each participant will be given two sets of pills. Some participants will receive the FMT treatment and others will receive a placebo. Neither the researchers nor the participants will know which treatment is given.